@article {Belogiannis2021.01.26.21250561, author = {Konstantinos Belogiannis and Venetia A. Florou and Paraskevi C. Fragkou and Stefanos Ferous and Loukas Chatzis and Aikaterini Polyzou and Nefeli Lagopati and Aikaterini Touliatou and Demetrios Vassilakos and Christos Kittas and Athanasios G. Tzioufas and Sotiris Tsiodras and Vassilis Gorgoulis}, title = {SARS-CoV-2 antigenemia/viremia masks seroconversion in a COVID-19 patient}, elocation-id = {2021.01.26.21250561}, year = {2021}, doi = {10.1101/2021.01.26.21250561}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Immune responses against SARS-CoV-2 have been vigorously analyzed. It has been proposed that a subset of mild or asymptomatic cases with undetectable antibodies may clear the virus in a T-cell cytotoxic-dependent manner, albeit recent data revealed the importance of B-cells in that regard. We hypothesized that underdiagnosed antigenemia/viremia may conceal humoral response possibly through immunocomplex formation. We report the first case of late-onset seroconversion detected following decline in antigenemia/viremia levels. Consequently, classification of at least a subset of COVID-19 cases as non-responders might not represent a true immunobiological phenomenon, rather reflect antibody masking due to prolonged antigenemia/viremia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the: National Public Investment Program of the Ministry of Development and Investment / General Secretariat for Research and Technology, in the framework of the Flagship Initiative to address SARS-CoV-2 (2020ΣΕ01300001); Horizon 2020 Marie Sklodowska-Curie training program no. 722729 (SYNTRAIN); Welfare Foundation for Social \& Cultural Sciences, Athens, Greece (KIKPE); H. Pappas donation; Hellenic Foundation for Research and Innovation (HFRI) grants no. 775 and 3782 and NKUA-SARG grant 70/3/8916.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained by the patients for the collection and processing of the samples as well as for the publication of this case report. This case report was conducted within the frame of -Emblematic action to handle SARS-CoV-2 infection: Epidemiological study in Greece via extensive testing for viral and antibody detection, sequencing of the virome and genetic analysis of the carriers-, which has been approved by the Ethics Committee of Medical School of National Kapodistrian University of Athens (Approval No. 317/12-06-2020). Ethics Committee board: 1) Prof E Kanavakis, 2) Prof G Vaiopoulos, 3) Prof I Kriari, 4) Prof M Manousakis, 5) A Tzioufas, 6) Prof A Tzonou, 7) Prof S Kitsiou-TzeliAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot pertinent to this manuscript.}, URL = {https://www.medrxiv.org/content/early/2021/01/29/2021.01.26.21250561}, eprint = {https://www.medrxiv.org/content/early/2021/01/29/2021.01.26.21250561.full.pdf}, journal = {medRxiv} }